• AstraZeneca completed a $2 billion equity investment in Summit Therapeutics on October 5, 2026, paying the full amount at closing.
• The investment gives it rights equivalent to approximately 12% of Summit's outstanding common stock, or 10.6% on a fully diluted basis.
• The companies entered clinical collaborations to evaluate sonesitatug vedotin and Datroway in combination with Summit's ivonescimab.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.